Related Experiment Video

Updated: Apr 27, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

12.7K

Current and future therapies for invasive aspergillosis

Matteo Bassetti1, Davide Pecori1, Paola Della Siega1

  • 1Infectious Diseases Division, Santa Maria Misericordia Hospital, Udine, Italy.

Pulmonary Pharmacology & Therapeutics
|July 5, 2014
PubMed

Insights

Invasive fungal infections are a growing global threat, especially for immunocompromised individuals. Early diagnosis and targeted treatment are crucial for managing pulmonary fungal infections like aspergillosis.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Pulmonology

Background:

  • Invasive fungal infections (IFIs) are increasing globally.
  • Immunocompromised patients (HIV, transplant recipients, immunosuppressive therapy) are at high risk.
  • Pulmonary fungal infections are associated with high mortality and diagnostic challenges.

Purpose of the Study:

  • To review the therapeutic management of invasive pulmonary aspergillosis.
  • To highlight the importance of early diagnosis and targeted treatment.
  • To discuss the role of new antifungal agents and diagnostic tools.

Main Methods:

  • Literature review focusing on therapeutic management strategies.
  • Analysis of recent advancements in antifungal compounds.
  • Discussion of diagnostic challenges and emerging tools.

Main Results:

  • New antifungal agents (lipid formulations of amphotericin B, newer azoles, echinocandins) are available.
  • Effective management relies on early and appropriate targeted treatment.
  • Despite advances, challenges in early diagnosis persist.

Conclusions:

  • Early diagnosis and prompt, targeted therapy are critical for successful management of respiratory fungal infections.
  • New diagnostic tools are needed to improve early detection.
  • Careful therapeutic management remains essential for improving outcomes in immunocompromised patients with IFIs.
Keywords:
AmphotericinAspergillusEchinocandinsGalactomannanPosaconazoleVoriconazole

More Related Videos

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

31.0K
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

12.1K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
118
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
655
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
102
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K